Fabrizio Gasparini

This inventor holds 1 USPTO granted patent. Top assignee: Novartis Ag. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Fabrizio Gasparini. Retrieved from https://idiyas.com/inventor/fabrizio-gasparini-ujj9b541

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

Average Co-Inventor Count = 1.0


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Fabrizio Gasparini: Innovator in Antibody Stabilization

Introduction

Fabrizio Gasparini is a notable inventor recognized for his contributions to the field of biotechnology. He is particularly known for his work on stabilizing antibodies, which play a crucial role in therapeutic applications. His innovative approach has garnered attention in the scientific community.

Latest Patents

Fabrizio holds a patent for TREM2 Stabilizing Antibodies. This patent represents a significant advancement in the development of therapeutic antibodies, which are essential for treating various diseases.

Career Highlights

Fabrizio Gasparini is currently employed at Novartis AG, a leading global healthcare company. His work at Novartis has allowed him to collaborate with some of the brightest minds in the industry, further enhancing his expertise and contributions to biotechnology.

Collaborations

One of his notable collaborators is Dominik Feuerbach. Together, they have worked on various projects that aim to improve the efficacy of therapeutic antibodies.

Conclusion

Fabrizio Gasparini's innovative work in stabilizing antibodies has made a significant impact in the field of biotechnology. His contributions continue to advance therapeutic applications and improve patient outcomes.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…